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PP-126 Analysis of the virological features and impact on
the efﬁcacy treated with peginterferon alfa-2a
and ribavirin in patients coinfected with HBV and
HCV
Jian-wu Yu*, Li-jie Sun, Yong-hua Zhao, Shu-chen Li. Department
of Infectious Diseases, Second Afﬁliated Hospital, Harbin
Medical University
Objective: To study the virological features and impact on the ef-
ﬁcacy treated with peginterferon alfa-2a and ribavirin in patients
coinfected with HBV and HCV.
Methods: The virological data of 50 patientswere retrospectively
analyzed and virological responses rates treated with peginter-
feron alfa-2a and ribavirin were investigated.
Results: HBV DNA level of patients coinfected with HBV and
HCV (4.6±0.9) log 10 copies/mL was signiﬁcantly lower than
that in HBV monoinfection group (5.9±1.2) log10 copies/mL
(t=5.964, P<0.01). HBeAg positive rate (12.0%, 6/50) of patients
co-infected with HBV and HCV group was signiﬁcantly lower
than that (45.3%,19/42) in HBV monoinfection group (χ2=12.743,
P<0.01). pEVR rate and ETVR rate (50.0%, 15/30; 90.0%, 27/30)
of patients with genotype 1 in HBV and HCV coinfection group
were signiﬁcantly higher than those (16.0%, 4/25; 56.0%, 14/25)
in monoinfection HCV group (χ2=6.971, P=0.008; χ2=8.307,
P=0.004); Relapse rate (55.6%, 15/27) of patients with geno-
type 1 in HBV and HCV coinfection group was signiﬁcantly higher
than that (21.4%, 3/14) in HCV monoinfection group (χ2=4.360,
P=0.037). The incidence of side effects (30%, 15/50) of pa-
tients in HBV and HCV coinfection group was signiﬁcantly higher
than that (13%, 6/46) in HCV monoinfection group (χ2=4.031,
P=0.045). Reactivation rate of HBV DNA (33.3%, 9/27) with HCV
SVR was signiﬁcantly higher than that of patients without SVR
(8.7%, 2/23) (χ2=4.393, P=0.036).
Conclusions: Compared with HCV monoinfected patients, pEVR,
ETVR and relapse rates of patients with genotype 1 in HBV and
HCV coinfection group were high, but they had similar SVR rates.
PP-127 Cloning, expression and identiﬁcation in
immunohistochemistry of humanized single-chain
Fv antibody against hepatitis C virus core protein
Yong-Zhi Lun*,1, Jun Cheng2, Zeng-Guo Yu1, Qi Wang2.
1Department of Pathogenic Biology, Medical College of Dalian
University; 2Institute of Infectious Disease, Beijing Ditan
Hospital
Objective: To clone and express humanized single chain Fv anti-
body (scFv) against hepatitis C virus core protein and identify its
application in immunohistochemistry.
Methods: The phage antibody library was panned by HCV core
protein, which was coated in microtiter plate. After ﬁve rounds
of biopanning, 60 phage clones were identiﬁed speciﬁc to HCV
core protein. The selected scFv was subcloned into the vector
pCANTAB5E for expression as E-tagged soluble scFv. The liver
tissue sections from normal person and patients with chronic
hepatitis C were immunostained.
Results: ELISA and immunohistochemistry study demonstrated
that the human single chain Fv antibody against hepatitis C
virus core protein has a speciﬁc binding character with parafﬁn-
embedded tissues from patients with chronic hepatitis C, but did
not react with liver tissues from healthy persons.
Conclusion: Humanized single chain Fv antibody to HCV core
protein has been identiﬁed by means of the phage display
technology.
PP-128 Metabolic implications of hepatitis C virus
infection & its correlation to steatohepatits in
chronic hepatitis C patients with and without
type 2 diabetes
Maged Refaat*, Howida Mansour, Hanan Farouk,
Mohamed Ghani, Maryam Abdrahman, Afaf Alem. Faculty of
medicine, Ain Shams University
Background: Chronic hepatitis C virus (HCV) infection is not a
simple viral infection; it has many metabolic and autoimmune
complications.
Objective: To investigate the impacts of chronic HCV infection
on glucose & lipid metabolism and its correlation with body mass
index (BMI) and hepatosteatosis in chronic HCV patients.
Patients and methods: (103) chronic HCV patients were involved
in this study, patients were classiﬁed into, Group I: 68 chronic
HCV patients with type 2 diabetes. Group II: 35 chronic HCV
patients without type 2 diabetes. In addition to 25 patients
with type 2 diabetes as controls; group III: calculation of BMI,
measurement of the waist/hip ratio and assessment of fasting
plasma insulin level was done by immune-enzymatic method,
assessment of insulin resistance state by Homeostatic Model
Assessment (HOMA-IR), detection of anti-HCV by 3rd generation
ELISA test & conﬁrmed by qualitative polymerase chain reaction
(PCR).
Results: Diabetic patients with chronic HCV infection have sig-
niﬁcantly higher fasting plasma insulin level, insulin resistance
state, liver enzymes & steatosis/ﬁbrosis scores than non dia-
betic patients,there was non signiﬁcant difference regarding BMI
between all groups. Positive correlations were found between
plasma insulin level, liver enzymes & steatohepatitis in patients
either they were diabetics or not.
Conclusion: Chronic HCV infection may be regarded as an in-
dependent risk factor for the development of type 2 diabetes.
HCV induces a state of insulin resistance which is the key step in
glucose intolerance, virus C induced steatohepatitis and hence
accelerates progression to cirrhosis.
PP-129 HCV genotype distribution in chronic hepatitis C
patients in a tertiary care hospital of Rawalpindi,
Pakistan
Adnan Raja*, Muhammad Umar, Hammamatul Bushra.
Gastroenterology and Hepatology division, Department of
Medicine, Holy Family Hospital, Rawalpindi, Pakistan
Background/Aims: Genotypes 1-6 have a worldwide distribution.
Types 1a and 1b are predominant in Northern Europe and North
America, and in Southern and Eastern Europe and Japan, respec-
tively. Type 3 in south Asia. Genotype 4 in Egypt, genotype 5 in
Central and South America and genotype 6 is common in China,
Japan and South East Asia. In Pakistan 3a is the commonest
genotype. As reported by different authors HCV genotype 3a
is associated with the most favorable outcome regarding ETR
and SVR after 24 weeks conventional Interferon and Ribavirin
therapy. The aim of this study is to ﬁnd out HCV Genotypes in
newly diagnosed chronic hepatitis C patients.
Methods: This observational study was conducted in chronic
hepatitis C patients treated with conventional interferon 3 MIU
thrice weekly and ribavirin 400 mg bid for 24 weeks. All patients
had raised ALT levels for last 06 months, had positive PCR for
HCV RNA by real time method and liver biopsy was done during
year 2006-2007. Genotyping was done on Roche Genotyping Kit.
Data was analyzed by using SPSS 13.0
Results: Out of 164 patients, 85.9% (n=141) were genotype 3a.
